The Sustainable Development Goals (SDGs), adopted at the UN Sustainable Development Summit held in September 2015, comprise 17 goals and 169 targets to create a future where no one is left behind and are global efforts to be accomplished by 2030.
In response to the diverse and changing social expectations and demands, the Sumitomo Pharma Group has identified Material Issues based on its belief that it is important to realize both contribution to social sustainability and its own sustained growth through the creation of value that only it can deliver by utilizing the Group’s capital (strengths) and also the development goals of the SDGs.
Going forward, the Sumitomo Pharma Group will continue to contribute to the realization of a sustainable society by addressing the issues facing society.
SDGs to which the Sumitomo Pharma Group contributes
While concentrating our efforts primarily on Goal 3, which is directly related to Sumitomo Pharma’s Mission and where we can best utilize our strengths, we are also actively working on Goal 8, 10, 12, 13, 16, and 17.
The Sumitomo Pharma Group’s Top Priority: Sustainable Development Goals and Targets
Goals
Targets
Pharmaceutical business (psychiatry & neurology, oncology, infectious diseases, etc.) and full scale launch of the Regenerative Medicine/Cell Therapy Business and the Frontier Business (3.4)
Addressing product safety and adverse reactions (3.4)
Providing and collecting product information (healthcare professionals) (3.4)
Initiatives to improve medicine-related literacy (3.4)
Operation of health and medical information website (3.4)
Initiatives aimed at appropriate use of antibiotics and countermeasures to antimicrobial resistance (AMR) (3.3)
Participation in GHIT Fund to develop medicines for malaria and other infectious diseases (3.3)
Participation in Access Accelerated to improve access to medicines for non-communicable diseases (NCDs) in developing countries (3.4)
Initiatives for safe delivery and sound child growth in Cambodia (3.1)
Support for children with intractable diseases (3.2)
Supporting daycare for sick children of single-parent families and families raising children with disabilities (3.8)
Health and productivity management (welfare of employees and promoting mental health) (3.8)
Promotion of Work Style Innovation aimed at more sophisticated work styles and a virtuous cycle in work-life balance (8.5)
CSR procurement (8.7)
Supporting active participation by people with disabilities through appropriate placement (8.5)
Health and productivity management (welfare of employees and promoting mental health) (8.5)
Supporting active participation by people with disabilities through appropriate placement (10.2)
Supporting independence and social reintegration of people with disabilities (10.2)
CSR procurement (10.2, 10.3)
Support for development of healthcare infrastructure and capacity building in developing countries (10.2)
Participation in Access Accelerated to improve access to medicines for NCDs in developing countries (10.2)
Initiatives for safe delivery and sound child growth in Cambodia (10.2)
Support for developing countries through company cafeterias and matching donations (10.2)
Maintenance and improvement of recycling rate for waste (12.4, 12.5)
Risk mitigation of environmental accidents (12.4)
Initiatives to reduce environmental impact throughout products' lifecycles (12.4, 12.5)
Stable product supply and quality assurance (12.6)
Risk mitigation of natural disasters (12.6)
Responding to TCFD (13.1)
Soliciting capital expenditure ideas to reduce CO2 emissions from within the company (13.1)
Utilizing fuel-efficient business vehicles (13.1)
Collaboration with Sumitomo Chemical group companies and Sumitomo Pharma's subsidiaries (SBT), and collaboration with supply chains (Scope3) (13.1)
Effective use of energy via COOL CHOICE, etc. (13.1)
Utilization of solar power generating systems (13.1)
Initiatives to reduce environmental impact throughout products' lifecycles (13.1)
Enhancement of corporate governance (16.5)
Pursuing compliance (16.1, 16.5)
CSR procurement (16.1, 16.2, 16.5)
Partnership activities for sustainable development（17.7）
Industry-academia-government collaborative R&D (academic institutions, startup companies, AMED, GHIT Fund, etc.)
Access Accelerated
IFPMA
JPMA (Japan Pharmaceutical Manufacturers Association)
People's Hope Japan
CDP
TABLE FOR TWO
Future Code
Malaria No More Japan
Other
